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ABSTRACT 
Human Papillomavirus (HPV) is the most common sexually transmitted disease of 
genital tract that may cause cervical cancer, the second most frequent type of cancer in 
South East Asia. By far, HPV vaccination is widely used for risk reduction; however, 
the rate of developing cervical cancer post-vaccination is still not well-studied. The aim 
of this study is to evaluate the association between HPV vaccination and development 
of cervical cancer in Southeast Asia. Analysis of data on HPV vaccination in Southeast 
Asia was performed, based on literature from 2010 to 2016 accessible in PubMed, 
Google Scholar, and ScienceDirect. Vaccination coverage rates and changes in cervical 
cancer incidence in particular countries were subjected to comparative analysis using 
Pearson’s correlation coefficient. The statistical analysis showed HPV vaccination 
coverage and cervical cancer incidence has negative correlation but not significant (r=-
0.04, p>0.05). This might due to HPV vaccination introduction is still at early stage 
(<10 years of implementation). In addition, 5 out of 9 countries are running the 
vaccination program as pilot project rather than nationwide program. Other factors 
may also influence the incidence of cervical cancer such as: genetics and lifestyle factor, 
socioeconomic status as well as having many children. Nevertheless, follow up study is 
needed to assess effect of HPV vaccination introduction and coverage to cervical cancer 
incidences in Southeast Asian countries. 
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Human Papillomavirus (HPV) is the most 
common sexually transmitted disease of 
genital tract that has high risk cause cervical 
cancer.(1) Most of HPV infected do not have 
any symptoms/asymptomatic. However, the 
persistence of HPV infection may result in 
the development of cervical cancer.(2)  
Current estimates of cervical cancer in the 
world in 2012 indicate 527.624 diagnosed 
annually and 265.672 are died from this 
disease. That makes cervical cancer as the 
fourth ranks cause of cancer death in the 
world.(3) While in Southeast Asia, cervical 
cancer become the second most frequent type 
of cancer, and become one of the highest 
incidence rates of cervical cancer in the world 
with 50.566 incidences and 23.989 number of 
deaths annually in 2012.(1)(4) In fact, data 
from World Health Organization (WHO) said 
that cervical cancer in Southeast Asia is 
contributing to nearly 35% of the global 
burden of disease which become major public 
health program.(5) 
Human Papillomavirus (HPV) associated 
with cervical cancer is considered as 
carcinogenic to human that based on the 
strong, consistent, and persistent between 
infections with the diseases.(6)(7) HPV 
vaccination is proved significantly reduces 
the HPV related disease; cervical cancer and 
provide high protection against it.(5)(2) 
HPV vaccine works by stimulating 
antibody-mediated immunity, that will make 
neutralizing antibody before HPV virus 
infects the host cells by recognizing and 
inactivating it.(8) The vaccines that are 
available in the market: Cervarix, Gardasil, 
and Gardasil 9. Cervarix, only works for HPV 
types 16 and 18. Gardasil vaccine have the 
ability to high level of protection from types 
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6, 11, 16, and 18. While Gardasil 9 gives 
additionally protection against HPV types 6, 
11, 31, 33, 45, 52, and 58.(1)(8) Both types of 
vaccines are approved in around 100 
countries globally and have a known duration 
of protection of at least 5 years. However, 
since Gardasil 9 is still newer vaccine, it still 
has not been acceptable by WHO and 
approved in Asian countries yet.(1) 
WHO recommended HPV vaccine should 
be implemented as national immunization 
programs and strategy by government in 
order to prevent cervical cancer. The strategy 
itself including training the health workers, 
give education, sexual, and reproductive 
health information to the people specially 
females about diagnosis, screening, and 
treatment of HPV related with cervical 
cancer, introduction to HPV vaccination as 
cervical cancer prevention. Especially, 
increased access to screening and treatment 
services.(9)(2) 
Besides cervical cancer, HPV vaccine is 
found out to be effective in prevent other 
cancers from anogenital tract such as anus, 
vagina, penis, vulva, and oropharynx.(10)(8) 
Therefore, HPV vaccination is offer simple 
and effective strategy widely to reduce the 
risk of cervical cancer. However, the rate of 
developing cervical cancer post-vaccination is 
still not well-studied. The objective of this 
review is to evaluate the association between 
HPV vaccination and development of cervical 
cancer in Southeast Asia. 
 
METHODS 
Data Collection 
Analysis of data on HPV vaccination in 
Southeast Asia was performed, based on 
literature from 2010 to 2016 accessible in 
PubMed, Google Scholar, and ScienceDirect, 
using the following keywords: “HPV 
vaccination”,” Cervical Cancer”, and 
“Southeast Asia”. 
For each included study, the following key 
information was extracted: country, vaccine 
coverage, vaccine status, year of introduction, 
and incidence of HPV (see appendix A1).  
 
Statistical analysis 
Vaccination coverage rates and change in 
cervical cancer incidence in particular 
countries were subjected to comparative 
analysis using Pearson’s correlation 
coefficient with R software. 
 
 
Table A1. Results of data collection 
 
Country Vaccine_Coverage Vaccine_Status  Vac_Year B_Inc A_Inc delta_inc 
Brunei 
Darussalam 93 Y 
2012-
2015 20 16.9 -3.1 
Malaysia 94.33 Y 2010 16 15.6 -0.4 
Vietnam  96 Pilot Pilot 20.5 10.6 -9.9 
Cambodia 77.8 Pilot 2015 38 23.8 -14.2 
Indonesia 76.6 Pilot 2012 16 17.3 1.3 
Lao PDR 76.9 Pilot Pilot 17 12.5 -4.5 
Philippines 70 Y 2015 21 16 -5 
Singapore 8.8 Y 2010 13 8.1 -4.9 
Thailand  60 Pilot 2014 19.5 17.8 -1.7 
Vaccine_Status: Y = National Program; Vac_Year : Year of vaccine introduced; B_Inc : Incidence 
rate before Vaccine introduced; A_Inc: After vaccine intro; delt_inc : differences 
 
RESULTS AND DISCUSSION 
In this study, HPV vaccination coverage 
and incidence of cervical cancer of 9 
Southeast Asia countries were collected 
(Brunei, Cambodia, Indonesia, Lao PDR, 
Malaysia, Philippines, Singapore, Thailand, 
and Vietnam). There are only nine out of 
eleven countries in Southeast Asia were 
subjected. Since there are no available data 
for Myanmar and Timor Leste and the HPV 
vaccine in those two countries have not being 
introduced yet even become their national 
program.(4)  
Five countries in Southeast Asia still in 
pilot program for HPV vaccine; Cambodia, 
Indonesia, Lao PDR, Thailand, Vietnam. 
Those countries that are still in pilot program 
may influence the data quality and may 
affect to the result. While the other four 
countries; Brunei, Malaysia, Philippines, and 
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Singapore already have their national 
program. In 2010, Malaysia and Singapore 
are being first countries that introduced HPV 
vaccination programs in ASEAN.(1)(11)  
In the end, the result from statistical 
analysis showed HPV vaccination coverage 
and cervical cancer incidence in Southeast 
Asian population has negative correlation 
but not significant (r=-0.04, p>0.05). It might 
be due to limited data since there are two 
countries that are being eliminated; no data 
available from Myanmar and Timor Leste, 
five out of nine countries (Cambodia, 
Indonesia, Lao PDR, Thailand, Vietnam) are 
running the vaccination program as pilot 
project rather than nationwide program, 
while only four countries (Brunei, Malaysia, 
Philippines, and Singapore) have their 
nationwide program for HPV vaccination, M 
alaysia and Singapore the first countries that 
introduced it in Southeast Asia.  
In addition, several factors may also 
influences the result; first the HPV vaccine in 
developing country, the database system that 
record medical activity is not well established 
and other factors like genetics and lifestyle 
factor, socioeconomic status as well as having 
many children. Such factors might produce 
less statistically powerful result. Moreover, 
to achieve more powerful result, 
establishment of a system to record medical 
activity is required. In order to analyze in 
more reliable and valid data to evaluate 
association between HPV vaccination and 
cervical cancer more deeply 
 
 
 
Figure A2. Scatter plot of HPV vaccination against cervical cancer 
 
 
CONCLUSION 
Overall, the analysis showed it is not really 
significant result. Since HPV vaccination 
introduction is still at early stage (<10 years 
of implementation). Nevertheless, follow up 
study is needed to assess effect of HPV 
vaccination introduction and coverage to 
cervical cancer incidences in Southeast Asian 
countries 
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